DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,767 filers reported holding DANAHER CORPORATION in Q4 2020. The put-call ratio across all filers is 0.97 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $16,461,590 | -0.1% | 66,351 | -3.3% | 3.09% | +7.0% |
| Q2 2023 | $16,472,305 | -6.2% | 68,635 | -1.5% | 2.89% | -11.3% |
| Q1 2023 | $17,567,082 | -6.5% | 69,700 | -1.6% | 3.26% | -11.0% |
| Q4 2022 | $18,794,269 | +0.9% | 70,810 | -1.9% | 3.66% | -3.3% |
| Q3 2022 | $18,635,000 | +2.4% | 72,148 | +0.5% | 3.78% | +11.5% |
| Q2 2022 | $18,207,000 | -13.7% | 71,818 | -0.1% | 3.39% | +1.4% |
| Q1 2022 | $21,086,000 | -11.8% | 71,883 | -1.1% | 3.35% | -7.2% |
| Q4 2021 | $23,915,000 | -20.4% | 72,688 | -26.3% | 3.61% | -6.7% |
| Q3 2021 | $30,034,000 | +11.5% | 98,654 | -1.7% | 3.87% | +13.4% |
| Q2 2021 | $26,938,000 | +4.4% | 100,380 | -12.5% | 3.41% | +137.0% |
| Q1 2021 | $25,812,000 | -4.9% | 114,680 | -6.1% | 1.44% | +0.6% |
| Q4 2020 | $27,131,000 | +4.6% | 122,136 | +1.3% | 1.43% | -2.8% |
| Q3 2020 | $25,950,000 | +21.8% | 120,514 | +0.1% | 1.47% | +11.3% |
| Q2 2020 | $21,298,000 | +27.5% | 120,443 | -0.2% | 1.32% | +9.4% |
| Q1 2020 | $16,703,000 | -12.1% | 120,677 | -2.5% | 1.21% | +17.8% |
| Q4 2019 | $19,004,000 | +3.9% | 123,820 | -2.2% | 1.03% | -4.0% |
| Q3 2019 | $18,293,000 | +0.8% | 126,654 | -0.2% | 1.07% | -2.6% |
| Q2 2019 | $18,140,000 | +0.4% | 126,927 | -7.2% | 1.10% | -2.6% |
| Q1 2019 | $18,064,000 | +22.7% | 136,830 | -4.2% | 1.13% | +9.9% |
| Q4 2018 | $14,721,000 | -11.6% | 142,761 | -6.8% | 1.02% | +7.0% |
| Q3 2018 | $16,648,000 | +7.4% | 153,213 | -2.5% | 0.96% | +2.5% |
| Q2 2018 | $15,499,000 | -6.9% | 157,065 | -7.6% | 0.94% | -5.7% |
| Q1 2018 | $16,646,000 | +2.0% | 170,014 | -3.3% | 0.99% | +4.5% |
| Q4 2017 | $16,315,000 | +3.4% | 175,770 | -4.5% | 0.95% | +1.0% |
| Q3 2017 | $15,785,000 | -1.4% | 184,020 | -3.0% | 0.94% | -3.9% |
| Q2 2017 | $16,008,000 | -0.0% | 189,695 | +1.3% | 0.98% | -4.6% |
| Q1 2017 | $16,010,000 | +6.3% | 187,183 | -3.3% | 1.02% | -3.5% |
| Q4 2016 | $15,062,000 | -0.4% | 193,499 | +0.3% | 1.06% | -4.4% |
| Q3 2016 | $15,116,000 | -22.7% | 192,834 | -0.4% | 1.11% | -17.9% |
| Q2 2016 | $19,561,000 | +8.2% | 193,670 | +1.6% | 1.35% | +0.4% |
| Q1 2016 | $18,080,000 | +4.2% | 190,600 | +2.0% | 1.35% | +0.2% |
| Q4 2015 | $17,352,000 | +6.6% | 186,825 | -2.2% | 1.34% | +2.8% |
| Q3 2015 | $16,280,000 | -6.2% | 191,054 | -5.8% | 1.31% | +1.5% |
| Q2 2015 | $17,363,000 | -1.6% | 202,868 | -2.4% | 1.29% | -4.3% |
| Q1 2015 | $17,649,000 | +4.9% | 207,874 | +5.9% | 1.35% | -1.1% |
| Q4 2014 | $16,832,000 | +13.7% | 196,382 | +0.8% | 1.36% | +7.1% |
| Q3 2014 | $14,804,000 | -12.9% | 194,839 | -9.8% | 1.27% | -12.1% |
| Q2 2014 | $17,006,000 | -4.0% | 215,999 | -8.5% | 1.45% | -0.2% |
| Q1 2014 | $17,710,000 | -6.4% | 236,137 | -3.7% | 1.45% | -15.1% |
| Q4 2013 | $18,931,000 | +19.1% | 245,224 | +6.9% | 1.71% | -10.6% |
| Q3 2013 | $15,901,000 | +5.4% | 229,387 | -3.7% | 1.91% | -1.3% |
| Q2 2013 | $15,080,000 | – | 238,224 | – | 1.94% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |